Payment overview · 2025
General Payments
$238.36
7 reported records · 7 companies
Healthcare provider profile · identity verified
Neil Richard, MD
Allopathic & Osteopathic Physicians|Family Medicine · WESTERVILLE, OH · NPI 1801865670
Verified facts
What the public records show
CMS Open Payments records show Neil Richard, MD received $238.36 in general payments during 2025 across 7 reported records.
ASAHI INTECC USA, INC. accounted for 56.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $134.75 | 56.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.57 | 8.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.54 | 8.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.63 | 7.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.16 | 6.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.09 | 6.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.62 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $238.36 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $134.75 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 724 | 211 |
| Levothyroxine Sodium | Levothyroxine Sodium | 658 | 128 |
| Eliquis | Apixaban | 524 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 427 | 109 |
| Furosemide | Furosemide | 366 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 350 | 74 |
| Gabapentin | Gabapentin | 339 | 77 |
| Losartan Potassium | Losartan Potassium | 337 | 75 |
| Trazodone Hcl | Trazodone Hcl | 329 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 319 | 80 |
| Lisinopril | Lisinopril | 300 | 81 |
| Potassium Chloride | Potassium Chloride | 298 | 62 |
| Omeprazole | Omeprazole | 268 | 67 |
| Sertraline Hcl | Sertraline Hcl | 260 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 244 | 40 |
| Donepezil Hcl | Donepezil Hcl | 232 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 39 |
| Memantine Hcl | Memantine Hcl | 180 | 23 |
| Mirtazapine | Mirtazapine | 173 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 43 |
| Simvastatin | Simvastatin | 165 | 38 |
| Metformin Hcl | Metformin Hcl | 151 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 142 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 29 |
| Carvedilol | Carvedilol | 128 | 37 |
| Myrbetriq | Mirabegron | 118 | 15 |
| Allopurinol | Allopurinol | 111 | 27 |
| Tramadol Hcl | Tramadol Hcl | 109 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 101 | 14 |
| Ezetimibe | Ezetimibe | 100 | 18 |
| Prednisone | Prednisone | 100 | 42 |
| Alendronate Sodium | Alendronate Sodium | 94 | 20 |
| Famotidine | Famotidine | 93 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 33 |
| Divalproex Sodium | Divalproex Sodium | 87 | 16 |
| Gemtesa | Vibegron | 84 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 83 | 22 |
| Ozempic | Semaglutide | 82 | 14 |
| Primidone | Primidone | 81 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 79 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 28 |
| Methenamine Hippurate | Methenamine Hippurate | 78 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 43 |
| Torsemide | Torsemide | 76 | 17 |
| Cephalexin | Cephalexin | 74 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 14 |
| Galantamine Hbr | Galantamine Hbr | 72 | suppressed |
| Latanoprost | Latanoprost | 72 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 71 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 11 |
| Januvia | Sitagliptin Phosphate | 68 | 13 |
| Nystatin | Nystatin | 68 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 15 |
| Farxiga | Dapagliflozin Propanediol | 64 | suppressed |
| Atenolol | Atenolol | 61 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 18 |
| Xarelto | Rivaroxaban | 59 | 17 |
| Levetiracetam | Levetiracetam | 58 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | suppressed |
| Bupropion Xl | Bupropion Hcl | 53 | 12 |
| Enoxaparin Sodium | Enoxaparin Sodium | 53 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 15 |
| Finasteride | Finasteride | 49 | 16 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 24 |
| Celecoxib | Celecoxib | 48 | 13 |
| Warfarin Sodium | Warfarin Sodium | 46 | 12 |
| Montelukast Sodium | Montelukast Sodium | 45 | 17 |
| Spironolactone | Spironolactone | 45 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 12 |
| Amoxicillin | Amoxicillin | 42 | 24 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 19 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 11 |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Budesonide Ec | Budesonide | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | suppressed |
| Trimethoprim | Trimethoprim | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 21 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 19 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | 13 |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | 18 |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Letrozole | Letrozole | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | 11 |
| Linzess | Linaclotide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 12 |
| Jardiance | Empagliflozin | 19 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Klayesta | Nystatin | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lasix | Furosemide | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $238.36 · 7 records | ASAHI INTECC USA, INC. | AIRSUPRA, Asahi Peripheral Vascular Wires, MOUNJARO, QULIPTA, Symbravo, UBRELVY, XIFAXAN, YUPELRI, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error